Skip to content

Clinical trials

Phase 3 trials in Spain with unknown status

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Phase: Phase 3 Status: Unknown status Country / region: Spain Clear all

138 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20021
20031
20042
20053
20064
20075
20086
20091
20104
20119
201212
20136
20146
20155
201613
201710
20184
20194
20209
20219
202210
20237

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status138

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Hospital General Universitario Elche7
European Organisation for Research and Treatment of Cancer - EORTC6
Aragon Institute of Health Sciences4
Centro Universitario La Salle4
Hospital Universitari Vall d'Hebron Research Institute4
Hospital Universitari de Bellvitge4
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau3
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla3
Universidad Complutense de Madrid3
University of Leicester3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
COVID-197
Breast Neoplasms6
Cardiovascular Diseases5
Apnea4
Colorectal Neoplasms4
Hypercapnia4
Hypoxia4
Pain4
Coronary Artery Disease3
Melanoma3

Trials

Showing 1 to 25 of 138. Each trial links to its page on Pharma Observatory.

38 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.